ONO-4059Highly potent and selective oral Btk inhibitor CAS# 1351635-67-0 |
- Iloperidone hydrochloride
Catalog No.:BCC4212
CAS No.:1299470-39-5
- Prucalopride
Catalog No.:BCC5055
CAS No.:179474-81-8
- LY310762
Catalog No.:BCC5052
CAS No.:192927-92-7
- SB271046
Catalog No.:BCC5057
CAS No.:209481-20-9
- Desvenlafaxine Succinate
Catalog No.:BCC5048
CAS No.:386750-22-7
- Desvenlafaxine
Catalog No.:BCC5038
CAS No.:93413-62-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1351635-67-0 | SDF | Download SDF |
| PubChem ID | 89455219 | Appearance | Powder |
| Formula | C25H24N6O3 | M.Wt | 456.5 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 29 mg/mL (63.53 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 6-amino-7-(4-phenoxyphenyl)-9-[(3S)-1-prop-2-enoylpiperidin-3-yl]purin-8-one | ||
| SMILES | C=CC(=O)N1CCCC(C1)N2C3=C(C(=NC=N3)N)N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5 | ||
| Standard InChIKey | KSUDUUBCXJUFRL-SFHVURJKSA-N | ||
| Standard InChI | InChI=1S/C25H24N6O3/c1-2-21(32)29-14-6-7-18(15-29)31-24-22(23(26)27-16-28-24)30(25(31)33)17-10-12-20(13-11-17)34-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | The product is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor with an IC50 in the sub-nM range.
IC50 value: sub-nM range [2]
Target: Btk
in vitro: ONO-4059 ( analog ) is a selective, once-daily, oral inhibitor of BTK, which has been shown to play a role in the survival and proliferation of malignant B-cells. ONO-4059 (analog) shows a favourable safety profile along with promising efficacy in this difficult-to-treat patient population. [1]
in vivo: ONO-4059 (analog) has demonstrated anti-tumour activity in several pre-clinical models.[1] ONO-4059 (analog) potently and dose-dependently reverse clinical arthritis and prevented bone damage in the CIA model.[2] References: | |||||
ONO-4059 Dilution Calculator
ONO-4059 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1906 mL | 10.9529 mL | 21.9058 mL | 43.8116 mL | 54.7645 mL |
| 5 mM | 0.4381 mL | 2.1906 mL | 4.3812 mL | 8.7623 mL | 10.9529 mL |
| 10 mM | 0.2191 mL | 1.0953 mL | 2.1906 mL | 4.3812 mL | 5.4765 mL |
| 50 mM | 0.0438 mL | 0.2191 mL | 0.4381 mL | 0.8762 mL | 1.0953 mL |
| 100 mM | 0.0219 mL | 0.1095 mL | 0.2191 mL | 0.4381 mL | 0.5476 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Description:
IC50: 2.2 nM for Btk kinase activity
Bruton’s tyrosine kinase (Btk) is a key regulator of the B-cell receptor (BCR) pathway and abberant BCR signaling has been implicated in the survival of malignant B-cells. Previous studies indicate that targeting Btk is effective in the treatment of B-cell malignancies. ONO-4059 is a highly potent and selective oral Btk inhibitor.
In vitro: ONO-4059 inhibited the TMD-8 cell growth and Btk phosphorylation in a concentration-dependent manner. Furthermore, the decrease in Btk phosphorylation subsequently down-regulated Erk phosphorylation. After the combination of ONO-4059 with doxorubicin, etoposide, vincristine and dexamethasone, increased apoptosis ratio was observed, 25, 20, 17 and 29%, respectively [1].
In vivo: For the 100-200 mm3 tumour groups, tumour growth inhibition at the final treatment day was 23% in QD, 72.9% in BD and 100% in dose mixed in food, groups respectively. For the 400-450 mm3 tumour groups, no growth inhibition was observed in the QD group and, growth inhibitions of 27.5% in BD and 100% in dose mixed in food were observed. The PK concentration and phosphorylated Btk inhibition levels of those animals whose dose was mixed in with food were higher than that of other treatment groups [2].
Clinical trial: ONO-4059 is a highly potent and selective oral Btk inhibitor that shows a favourable safety profile along with promising efficacy in this difficult-to-treat patient population with relapsed/refractory B-Cell lymphoma [3].
Reference:
[1] Tomoko Yasuhiro, Toshio Yoshizawa, Joseph TP Birkett, and Kazuhito Kawabata. ONO-4059, A Novel Bruton’s Tyrosine Kinase (Btk) Inhibitor: Synergistic Activity In Combination With Chemotherapy In a ABC-DLBCL Cell Line. 2013; Blood: 122 (21): 5151 - 5151
[2] Toshio Yoshizawa, Tomoko Yasuhiro, Hideyuki Honda, and Kazuhito Kawabata. ONO-4059—a Potent and Selective Reversible Bruton’s Tyrosine Kinase (Btk) Inhibitor: Single Agent, Twice Daily (BD) Dosing and Dosing with Food Results in Sustained, High Trough Levels of ONO-4059, Translating into 100% Tumour Remission in a TMD-8 Xenograft Model. 2014; Blood: 124 (21) 4502 - 4502
[3] Simon Rule, Nimish Shah, Gilles Andre Salles et al. A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma. Blood. 2013 122 (21): 4397 – 4397.
- 21,23:24,25-Diepoxy-21,23-dimethoxytirucall-7-en-3-one
Catalog No.:BCN1581
CAS No.:1351617-74-7
- Amooracetal
Catalog No.:BCN6876
CAS No.:1351617-73-6
- Sarpogrelate hydrochloride
Catalog No.:BCC5247
CAS No.:135159-51-2
- H-DL-Ala-OMe.HCl
Catalog No.:BCC2854
CAS No.:13515-97-4
- H-Sar-OMe.HCl
Catalog No.:BCC3335
CAS No.:13515-93-0
- 2',7-Dihydroxy-5,8-dimethoxyflavanone
Catalog No.:BCN4041
CAS No.:1351338-14-1
- Z-Tyr-OMe
Catalog No.:BCC2746
CAS No.:13512-31-7
- Fmoc-Nva-OH
Catalog No.:BCC3302
CAS No.:135112-28-6
- Camelliaside A
Catalog No.:BCN3871
CAS No.:135095-52-2
- kb-NB77-78
Catalog No.:BCC5462
CAS No.:1350622-33-1
- Repaglinide
Catalog No.:BCC2504
CAS No.:135062-02-1
- MK-5172
Catalog No.:BCC1762
CAS No.:1350514-68-9
- HG-10-102-01
Catalog No.:BCC4271
CAS No.:1351758-81-0
- GNE-7915
Catalog No.:BCC5304
CAS No.:1351761-44-8
- H-Val-OtBu.HCl
Catalog No.:BCC3143
CAS No.:13518-40-6
- Sanggenol P
Catalog No.:BCN4766
CAS No.:1351931-30-0
- 3Beta-acetoxy-eupha-7,25-dien-24(R)-ol
Catalog No.:BCN1580
CAS No.:1352001-09-2
- AMG232
Catalog No.:BCC3992
CAS No.:1352066-68-2
- Schineolignin B
Catalog No.:BCN3623
CAS No.:1352185-26-2
- AZD6738
Catalog No.:BCC6505
CAS No.:1352226-88-0
- Pindolol
Catalog No.:BCC6881
CAS No.:13523-86-9
- Trijuganone C
Catalog No.:BCN3685
CAS No.:135247-94-8
- Pulchinenoside B
Catalog No.:BCN6554
CAS No.:135247-95-9
- EW-7197
Catalog No.:BCC6467
CAS No.:1352608-82-2
Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.[Pubmed:30815927]
Cancer Sci. 2019 Feb 27.
We evaluated the safety, efficacy, pharmacokinetics, pharmacodynamics and predictive biomarkers of tirabrutinib, a second-generation, enhanced-selectivity Bruton's tyrosine kinase inhibitor in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-cell NHL) and chronic lymphocytic leukemia (CLL). This was an open-label, multicenter, phase I study. Seventeen patients (male N = 8) with a median age of 70 years were enrolled in 4 dose cohorts (160 mg once daily [N = 3], 320 mg once daily [N = 3], 480 mg once daily [N = 4] and 300 mg twice daily [N = 7]); 4 patients had continued tirabrutinib administration as of 4 January 2018. The maximum tolerated dose was not reached. Pneumonitis (N = 1) was the dose-limiting toxicity for 300 mg twice daily. Common adverse events (AEs) were rash (35.3%) and vomiting (29.4%). Eight patients (47.1%) developed grade >/=3 AEs: neutropenia (23.5%), anemia (11.8%) and leukopenia (11.8%) were frequent. The overall response rate (>/=PR) was 76.5% (13/17 patients), including 4 DLBCL patients with no CD79A/B or MYD88 mutations, and 1 CLL patient with a TP53 mutation, providing promising data for future developments. Of 16 patients with measurable lesions during the screening period, 12 showed >/=50% reductions in tumor diameter. In many patients, the tumor size decreased soon after beginning treatment. The maximum serum concentration for tirabrutinib was 611, 1220, 1280 and 886 ng/mL on Day 1 and 484, 971 1940, and 961 ng/mL on Day 28 for Cohorts 1-4, respectively. Tirabrutinib pharmacokinetics were linear, with little accumulation following multiple doses. Tirabrutinib was well tolerated and showed promising efficacy for B-cell NHL/CLL.
Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement.[Pubmed:30011241]
SLAS Discov. 2018 Oct;23(9):919-929.
Bruton's tyrosine kinase (BTK) is a clinically validated target for B-cell leukemias and lymphomas with FDA-approved small-molecule inhibitors ibrutinib and acalabrutinib. Tirabrutinib (GS-4059/ONO-4059, Gilead Sciences, Inc., Foster City, CA) is a second-generation, potent, selective, irreversible BTK inhibitor in clinical development for lymphoid malignancies, including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). An accurate pharmacodynamic assay to assess tirabrutinib target coverage in phase 1/2 clinical studies will inform dose and schedule selection for advanced clinical evaluation. We developed a novel duplex homogeneous BTK occupancy assay based on time-resolved fluorescence resonance energy transfer (TR-FRET) to measure free and total BTK levels in a multiplexed format. The dual-wavelength emission property of terbium-conjugated anti-BTK antibody served as the energy donor for two fluorescent energy acceptors with distinct excitation and emission spectra. The assay was characterized and qualified using full-length purified recombinant human BTK protein and peripheral blood mononuclear cells derived from healthy volunteers and patients with CLL. We demonstrated assay utility using cells derived from lymph node and bone marrow samples from patients with CLL and DLBCL. Our TR-FRET-based BTK occupancy assay provides accurate, quantitative assessment of BTK occupancy in the clinical trial program for tirabrutinib and is in use in ongoing clinical studies.
Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.[Pubmed:28942659]
Expert Opin Investig Drugs. 2017 Nov;26(11):1249-1265.
INTRODUCTION: Over the last few years, several new synthetic drugs, particularly Bruton's tyrosine kinase (BTK), phosphatidylinositol 3-kinase (PI3K) and BCL-2 inhibitors have been developed and investigated in chronic lymphocytic leukemia (CLL). Areas covered: This review highlights key aspects of BTK, PI3K and BCL-2 inhibitors that are currently at various stages of preclinical and clinical development in CLL. A literature review of the MEDLINE database for articles in English concerning CLL, B-cell receptor, BCL-2 antagonists, BTK inhibitors and PI3K inhibitors, was conducted via PubMed. Publications from 2000 through July 2017 were scrutinized. The search terms used were acalabrutinib, ACP-196, BGB-3111, ONO-4059, GS-4059, duvelisib, IPI-145, TGR-1202, copanlisib, Bay 80-6946, buparlisib, BKM-120, BCL-2 inhibitors, venetoclax, ABT-263, navitoclax, CDK inhibitors, alvocidib, flavopiridol, dinaciclib, SCH 727,965, palbociclib, PD-0332991, in conjunction with CLL. Conference proceedings from the previous five years of the ASH and EHA Annual Scientific Meetings were searched manually. Additional relevant publications were obtained by reviewing the references from the chosen articles. Expert opinion: The use of new synthetic drugs is a promising strategy for the treatment of CLL. Data from ongoing and future clinical trials will aid in better defining the status of new drugs in the treatment of CLL.
